Charles Drew University of Medicine and Science
Trial Pipeline
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
NCT06615752
Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes
NCT05765214
Entre Herman@s: Promoting Health Among Latino MSM
NCT05805306
Obesity Group Visits. A Novel Way to Approach the Obesity Epidemic in an Inner-City Setting
NCT04725058
Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images
NCT03694145
Females of African American Legacy Empowering Self (FemAALES)
NCT02189876
Dance Dance Revolution (DDR) in Type 2 Diabetes
NCT00851019
Testosterone Gel Applied to Women With Pituitary Gland Problems
NCT00144391
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
NCT00004400
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
| Phase 4 | 1 |
What the Pipeline for Charles Drew University of Medicine and Science Shows
According to the ClinicalTrials.gov registry, Charles Drew University of Medicine and Science is linked to 9 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 11% of the sponsor's indexed portfolio — and 4 are already marked complete, representing roughly 44% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Charles Drew University of Medicine and Science reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Charles Drew University of Medicine and Science is HIV Infections with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.